{
  "pmcid": "8179178",
  "sha256": "aed6c88f15ac388e4723a0494ccdc39f87ffbe5ff9dc850e8ec55110d1c20915",
  "timestamp_utc": "2025-11-10T00:08:40.414133+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.499557823129255,
    "reading_ease": 29.68992630385489,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of the CAPAC Platform for Targeted Cancer Therapy"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either the CAPAC treatment (SQ3370) or conventional doxorubicin."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted in a preclinical setting using a syngeneic tumor model in mice."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either the CAPAC treatment (SQ3370) or conventional doxorubicin."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the maximum tolerated dose (MTD) of SQP33, measured over a 38-day period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 40 mice were randomised, with 20 in each group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The MTD of SQP33 was 19.1-times higher than conventional doxorubicin in mice."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were less frequent in the CAPAC group, with no severe events reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT04106492."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Shasqi, Inc."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}